Worldwide Clinical Trials Recognized with Coveted 2024 CRO Leadership Awards Based on Customer Feedback for 11th Consecutive Year
May 01 2024 - 8:00AM
Business Wire
Global contract research organization honored
as top outsourcing partner, earning high marks in several
categories from Industry Standard Research
Worldwide Clinical Trials (Worldwide), a leading global,
full-service contract research organization (CRO), has been
recognized for excellence in all five categories in the 2024 CRO
Leadership Awards, based on primary market research from Industry
Standard Research (ISR) Reports and presented by Clinical Leader
and Life Science Leader magazines. This marks the 11th consecutive
year that Worldwide is rated as a high-performing CRO based on
direct survey feedback from pharmaceutical and biotech
professionals, with this year’s distinction augmented by additional
honors as a Champion in several pivotal categories.
Highlights from the ISR data include Worldwide being named the
highest rated service provider for Project Management Quality,
outperforming all other Phase II/III CROs; achieving joint-first
position for Operational Excellence among Phase II/III CROs; rating
highest Phase II/III service provider for Biostatistics; and
outperforming all other Phase II/III CROs for Project Service
Delivery in Europe.
Worldwide achieved top marks from sponsor companies across all
five core categories, demonstrating comprehensive excellence
in:
- Capabilities (Overall, Big Pharma)
- Compatibility (Overall, Big Pharma, Small Pharma)
- Expertise (Overall, Big Pharma, Small Pharma)
- Quality (Overall, Big Pharma, Small Pharma)
- Reliability (Overall, Big Pharma, Small Pharma)
Additionally, Clinical Leader recognized organizations that
surpassed the weighted average by more than one standard deviation
in each of the core categories, earning them the ‘Champion’ title.
Worldwide was honored as a Champion in:
- Compatibility (Big Pharma)
- Expertise (Big Pharma)
- Quality (Big Pharma)
- Reliability (Big Pharma)
"Worldwide's recognition as a top CRO underscores the dedication
our team members have to exceed expectations through collaboration
and a real understanding of what our customers want and need," said
Peter Benton, president and CEO of Worldwide. "We are grateful for
this industry acknowledgment, marking yet another milestone in our
ongoing journey to improve patient lives through clinical research
programs, and we remain committed to continued partnerships with
our customers to drive innovation and meaningful advancement in
healthcare."
Worldwide’s partnership approach with its customers is anchored
in transparent communication, responsiveness, and personalized
attention. Earlier this year, Worldwide released the results of its
2024 industry survey, a report that examines the changing
perceptions about large and midsize CROs within the pharmaceutical
and biotech sectors. The survey data revealed current challenges
sponsors are facing with large CROs while highlighting the
importance of CRO partnerships and flexibility – underscoring the
benefits of Worldwide’s business model. Learn more here.
The CRO Leadership Awards serve as a beacon of trust and quality
within the pharmaceutical industry, helping stakeholders identify
CRO partners that are not just capable, but exemplary. This year's
awards saw evaluations of 42 contract research organizations across
over 20 performance metrics, grounded in robust, direct feedback
from customers regarding their experiences over the past 18 months
to reflect real-world performance and reliability.
Learn more about Worldwide’s services and achievements here.
About Worldwide Clinical Trials:
Worldwide Clinical Trials (Worldwide) is a leading full-service
global contract research organization (CRO) that works in
partnership with biotechnology and pharmaceutical companies to
create customized solutions that advance new medications – from
discovery to reality. Worldwide’s capabilities include
bioanalytical laboratory services, Phase I-IV clinical trials, and
post-approval and real-world evidence studies – all powered by an
accessible team of clinicians, scientists, and researchers who
bring first-hand expertise and a collaborative, personalized
approach to each clinical program. Worldwide is therapeutically
focused on neuroscience, oncology, rare diseases, and
cardiometabolic and inflammatory disease. Its global footprint
spans nearly 60 countries with more than 3,500 team members. For
more information, visit www.worldwide.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501013523/en/
Jill Mastrangelo Jill.Mastrangelo@Worldwide.com